Search

Since its emergence, canine parvovirus type 2 (CPV-2) has caused disease pandemics with severe gastroenteritis signs, infecting especially puppies. As a consequence of CPV rapid evolution a variety of genetic and antigenic variants have been reported circulating worldwide. The detection of additional variants of CPV circulating in the dog population in Portugal suggests monitoring of the disease is useful. The objectives of this study were to further detect and characterize circulating field variants from suspected CPV diseased dogs that were admitted to veterinary clinics distributed throughout the country, during 2012–2014. Of the 260 fecal samples collected, 198 were CPV positive by PCR, and CPV antigen was detected in 61/109 samples by Immunochromatographic (IC) test. The restriction fragment length polymorphism (RFLP) analysis of 167 samples revealed that 86 were the CPV-2c. Sequence analysis of the 198 strains confirmed that CPV-2c were the dominant variant (51.5%), followed by CPV-2b (47.5%) and CPV-2a (1%). The variants were irregularly distributed throughout the country and some were detected with additional non-synonymous mutations in the VP2 gene. Phylogenetic analysis demonstrated that the isolates were similar to other European strains, and that this virus continues to evolve. [ABSTRACT FROM AUTHOR]

Canine parvovirus (CPV) is the most important enteric virus infecting canids worldwide. The purpose of this study was to detect CPV in naturally infected dogs from several veterinary clinics distributed throughout Portugal between 2012 and 2014 and to identify risk factors associated with CPV infection. From 209 dogs suspected of being infected with CPV, historical data and clinical signs were collected. Fecal samples were screened for CPV by PCR assay and those positive were confirmed by sequencing. The data was analyzed using logistic regression to investigate associations between each of the predisposing factors and CPV status. Of the samples collected, 77.5% tested CPV-positive. Statistical analysis showed that animals in the three age categories ( p < 0.001) were at list 12 times more likely to be CPV-positive than older animals. The anthelminthic treatment [OR = 0.45, p = 0.04] and the rectal temperature (hypothermia, [OR = 0.12, p = 0.004]) contributed to decrease the likelihood of the dogs be infected with CPV. On the other hand, clinical signs such as depression [OR = 4.4, p = 0.02] and dehydration status [OR = 2.38, p = 0.001] made dogs more likely to be CPV-infected. The results indicate that although having a high morbidity, only 18% of the Portuguese dog population died in the study. Some of the risk factors identified in this study have not been commonly reported, yet they are easy to obtain and can be used as prognostic indicators in the veterinary practice. [ABSTRACT FROM AUTHOR]

• Excellent antibacterial activity of dalbavancin vs. methicillin-resistant Staphylococcus aureus (MRSA) in infection rat model. • Efficacy of dalbavancin confirmed for treatment of osteomyelitis caused by MRSA. • Efficacy shown by microbiological eradication and histological bone improvement. • The effect of dalbavancin was more pronounced in rats treated for 14 days. Bacterial osteomyelitis is a major clinical challenge in human and veterinary patients. This infection is an infrequent but feared complication of orthopedic surgery and is mainly caused by methicillin-resistant Staphylococcus aureus (MRSA). The aim of this study was to evaluate the efficacy of dalbavancin (dosed for either 7 or 14 days) in an MRSA-osteomyelitis tibial bone model. A total of 39 rats were included in the study. All animals received an inoculum of a clinical strain of MRSA (106 colony-forming units [CFU]) injected into the proximal tibia under general anesthesia. Dalbavancin was injected intraperitoneally for 7 or 14 days in 13 animals each; the remaining 13 animals received saline solution. After treatment, the animals were sacrificed. Infected tibiae were recovered for histological evaluation and microbiological analysis (MRSA count per gram of bone). Rats that received dalbavancin showed a statistically significant reduction of MRSA counts compared with the control group: median 0 CFU/g bone (14 days of dalbavancin) vs. 70 CFU/g bone (7 days of dalbavancin) and 1600 CFU/g bone (control). Histological evaluation showed typical signs of osteomyelitis in the control group, whereas there were no signs of bone infection in 92% of the rats that received 14 days of dalbavancin. According to this model, dalbavancin seems to have good efficacy for treating serious Gram-positive bone infections, including those caused by MRSA. [ABSTRACT FROM AUTHOR]